ニュース

Why Scale-Up Surprises Happen The development laboratory is a controlled, forgiving environment. The scientist is present at every step, making small adjustments and observations that never make it into the batch record. The equipment is flexible. The batch size is small enough that a failed experiment costs almost nothing. GMP manufacturing is the opposite. The […]

Natural Nanoparticles with Pharmaceutical Potential Every cell in the human body releases extracellular vesicles (EVs). These membrane-bound particles, ranging from roughly 30 nanometres to several micrometres in size, carry proteins, lipids, nucleic acids, and metabolites between cells. They are natural intercellular communication vehicles, evolved to transfer biological cargo across biological barriers. The pharmaceutical interest in […]

The Problem with Both Mistakes Under-supply stops a clinical trial. Patients cannot be dosed, sites go on hold, and the timeline slips in ways that are expensive and sometimes impossible to recover. The consequences are obvious and everyone works hard to avoid them. Over-manufacturing is less dramatic but equally costly. A 10 kilogram GMP batch […]

Two Goals That Sound the Same but Are Not Topical and transdermal are often used interchangeably. They should not be. A topical formulation delivers drug to the skin or the tissue beneath it. The goal is local effect: treat a skin condition, reduce inflammation in a joint just below the surface, or act on target […]

The Appeal Is Real. So Are the Traps. Drug repurposing, taking a compound with an established safety profile and investigating it for a new indication, offers a genuinely shorter path to the clinic. You start with human safety data. You may have existing PK characterisation. You understand the compound’s behaviour in ways that a completely […]

Why the Lung Is Worth the Complexity The lungs offer a drug delivery surface area of roughly 70 to 100 square metres, a thin alveolar membrane, rich vasculature, and, for respiratory conditions, direct access to the target tissue. For drugs targeting the lung, inhalation delivers drug precisely where it is needed, at doses a fraction […]

Excipients Are Not Passive The word inactive ingredient implies that excipients do nothing. That is a convenient regulatory classification, not a pharmacological reality. Excipients interact with APIs chemically. They compete for water. They affect the pH microenvironment within a tablet. They adsorb onto drug particles and change their surface properties. They can accelerate degradation pathways, […]

The Solubility Wall Oral bioavailability depends on two things: how much drug dissolves in the gastrointestinal tract and how much of the dissolved drug crosses the intestinal wall into the bloodstream. For BCS Class I drugs, both happen efficiently and bioavailability is high. For BCS Class II drugs, the drug dissolves poorly and absorption is […]

The Hardest Drugs to Make Oncology is consistently the largest therapeutic area in pharmaceutical development pipelines, and it is consistently the most technically demanding. The molecules tend to be highly potent. The patient populations are often defined by specific biomarkers, requiring precise clinical supply and diagnostic coordination. The tolerability window is narrow, making dose accuracy […]

The Model That Changed Biotech Twenty years ago, a credible pharmaceutical development programme needed laboratories, equipment, and scientists on the payroll. The idea that a five-person team could advance a drug candidate from lead optimisation to Phase II without owning a single centrifuge would have seemed implausible. Today it is routine. The virtual biotech model, […]

Deviations Are Not the Problem. The Response Is. In any GMP manufacturing environment, deviations will happen. A process parameter drifts outside its validated range. A raw material fails an incoming test. A batch record is completed incorrectly. These events are not evidence of a dysfunctional organisation. They are the normal noise of complex manufacturing. What […]

Why Your CDMO’s Inspection Record Is Your Problem Too When a regulatory agency inspects a contract manufacturing organisation, it is not just inspecting the CDMO. It is inspecting the GMP compliance of every product made at that site, including yours. A Form 483 observation or a warning letter to your CDMO does not automatically stop […]